DNLI Denali Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNLI

Price (delayed)

$22.9

Market cap

$3.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.6

Enterprise value

$2.96B

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...

Highlights
The quick ratio has soared by 60% year-on-year and by 20% since the previous quarter
Denali Therapeutics's equity has increased by 28% QoQ and by 8% YoY
DNLI's revenue has soared by 123% year-on-year but it is down by 2% since the previous quarter
Denali Therapeutics's gross profit has surged by 123% YoY but it has decreased by 2% QoQ
The net income is down by 12% year-on-year and by 8% since the previous quarter
The EPS has decreased by 9% YoY and by 5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.denalitherapeutics.com
Peers: MRVI MGTX NBIX

Key stats

What are the main financial stats of DNLI
Market
Shares outstanding
136.68M
Market cap
$3.13B
Enterprise value
$2.96B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.98
Price to sales (P/S)
26.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.34
Earnings
Revenue
$108.46M
EBIT
-$325.97M
EBITDA
-$315.59M
Free cash flow
-$262.55M
Per share
EPS
-$2.6
Free cash flow per share
-$2.09
Book value per share
$7.68
Revenue per share
$0.86
TBVPS
$11.63
Balance sheet
Total assets
$1.46B
Total liabilities
$417.81M
Debt
$53.03M
Equity
$1.04B
Working capital
$1.01B
Liquidity
Debt to equity
0.05
Current ratio
3.77
Quick ratio
3.67
Net debt/EBITDA
0.52
Margins
EBITDA margin
-291%
Gross margin
100%
Net margin
-300.6%
Operating margin
-314.2%
Efficiency
Return on assets
-24.6%
Return on equity
-35.7%
Return on invested capital
-36.9%
Return on capital employed
-29.7%
Return on sales
-300.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNLI stock price

How has the Denali Therapeutics stock price performed over time
Intraday
-0.04%
1 week
-1.84%
1 month
-11.62%
1 year
-32.82%
YTD
-17.66%
QTD
-17.66%

Financial performance

How have Denali Therapeutics's revenue and profit performed over time
Revenue
$108.46M
Gross profit
$108.46M
Operating income
-$340.74M
Net income
-$325.99M
Gross margin
100%
Net margin
-300.6%
DNLI's revenue has soared by 123% year-on-year but it is down by 2% since the previous quarter
Denali Therapeutics's gross profit has surged by 123% YoY but it has decreased by 2% QoQ
Denali Therapeutics's net margin has increased by 50% YoY but it has decreased by 10% from the previous quarter
DNLI's operating margin is up by 48% year-on-year but it is down by 11% since the previous quarter

Growth

What is Denali Therapeutics's growth rate over time

Valuation

What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
2.98
P/S
26.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.34
The EPS has decreased by 9% YoY and by 5% from the previous quarter
DNLI's price to book (P/B) is 38% less than its 5-year quarterly average of 4.8 and 29% less than its last 4 quarters average of 4.2
Denali Therapeutics's equity has increased by 28% QoQ and by 8% YoY
DNLI's revenue has soared by 123% year-on-year but it is down by 2% since the previous quarter
The stock's price to sales (P/S) is 89% less than its 5-year quarterly average of 237.3 and 28% less than its last 4 quarters average of 36.6

Efficiency

How efficient is Denali Therapeutics business performance
The ROS has increased by 50% YoY but it has decreased by 10% from the previous quarter
The return on equity has declined by 28% year-on-year and by 6% since the previous quarter
The return on invested capital has declined by 27% year-on-year and by 3.1% since the previous quarter
The return on assets has declined by 25% year-on-year and by 6% since the previous quarter

Dividends

What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNLI.

Financial health

How did Denali Therapeutics financials performed over time
The quick ratio has soared by 60% year-on-year and by 20% since the previous quarter
The current ratio has soared by 59% YoY and by 19% from the previous quarter
Denali Therapeutics's debt is 95% less than its equity
DNLI's debt to equity is down by 38% since the previous quarter and by 17% year-on-year
Denali Therapeutics's equity has increased by 28% QoQ and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.